Axogen, Inc.
As of Oct 22, 2026, Axogen is in Stage 3, the topping phase, now in week 2 (since Oct 14, 2026). It closed at $36.68, 29.1% below its 52-week high and below its 200-day average, which is rising.
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is AXGN early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
AXGN among Medical Devices6th of 141 by relative strength
All 141 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | TXG | Stage 2 · wk 48 | 99 | −7.8% |
| 2 | RCEL | Stage 2 · wk 13 | 98 | +40.8% |
| 3 | BFLY | Stage 2 · wk 26 | 98 | −26.0% |
| 4 | HAE | Stage 2 · wk 17 | 96 | +8.7% |
| 5 | GKOS | Stage 2 · wk 25 | 96 | +15.1% |
| 6 | AXGN | Stage 3 · wk 2 | 95 | −15.3% |
| 7 | NEOG | Stage 2 · wk 14 | 95 | −11.7% |
| 8 | BVS | Stage 2 · wk 15 | 95 | +10.5% |
Axogen: quick answers
What stage is Axogen in?
As of Oct 22, 2026, Axogen (AXGN) is in Stage 3, the topping phase. It entered Stage 3 on Oct 14, 2026 and is in week 2. What the four stages mean
Is Axogen in an uptrend?
Its uptrend has stalled. Axogen is in Stage 3, the topping phase that follows an advance. It trades 6.5% below its 200-day average, which is rising.
How far is Axogen from its 52-week high?
Axogen closed at $36.68 on Oct 22, 2026, 29.1% below its 52-week high of $51.73. Its 52-week low is $17.77.
How has Axogen performed over the past year?
As of Oct 22, 2026, Axogen is up 109.7% over the past year and up 18.3% so far in 2026.
Which sector and industry is Axogen in?
Axogen is in the Medical Devices industry, part of the Health Care sector.
About this companyHealth Care· Medical Devices
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.